Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Pharma-Bio Serv (PBSV) over the last 17 years, with Q4 2025 value amounting to $279666.0.

  • Pharma-Bio Serv's Cash from Operations rose 25660.31% to $279666.0 in Q4 2025 from the same period last year, while for Oct 2025 it was -$214886.0, marking a year-over-year increase of 6208.12%. This contributed to the annual value of -$214886.0 for FY2025, which is 6208.12% up from last year.
  • Latest data reveals that Pharma-Bio Serv reported Cash from Operations of $279666.0 as of Q4 2025, which was up 25660.31% from $236524.0 recorded in Q3 2025.
  • In the past 5 years, Pharma-Bio Serv's Cash from Operations registered a high of $1.1 million during Q3 2022, and its lowest value of -$1.2 million during Q2 2021.
  • Its 5-year average for Cash from Operations is $125333.6, with a median of $248307.5 in 2022.
  • Its Cash from Operations has fluctuated over the past 5 years, first soared by 36768.36% in 2023, then tumbled by 18017.77% in 2024.
  • Quarter analysis of 5 years shows Pharma-Bio Serv's Cash from Operations stood at $960350.0 in 2021, then tumbled by 72.92% to $260091.0 in 2022, then rose by 18.59% to $308436.0 in 2023, then plummeted by 74.57% to $78425.0 in 2024, then surged by 256.6% to $279666.0 in 2025.
  • Its last three reported values are $279666.0 in Q4 2025, $236524.0 for Q3 2025, and -$301590.0 during Q2 2025.